

Press Release**Q2 Income from Operations at Rs. 540 cr., PAT at Rs. 132 cr.**
(2nd Quarter & Half year, FY 2018 Consolidated Results)

Mumbai, 31st October, 2017: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 2nd quarter & half year ended 30th September 2017.

Q2 FY 2018 performance highlights (Consolidated, compared to Q2 FY 2017)

- Income from operations at Rs. 540 cr. against Rs. 516 cr., up 5%.
- EBITDA at Rs. 184 cr. against Rs. 183 cr., EBITDA at 34% of revenue.
- Profit after tax at Rs. 132 cr., against Rs. 131 cr., PAT at 24% of revenue.
- Total comprehensive income at Rs. 134 cr. against Rs. 125 cr. up 7%.

H1 FY 2018 performance highlights (Consolidated, compared to H1 FY 2017)

- Income from operations at Rs. 1014 cr. against Rs. 992 cr., up 2%.
- EBITDA at Rs. 314 cr. against Rs. 349 cr., down 10%, EBITDA at 31% of revenue.
- Profit after tax at Rs. 227 cr., against Rs. 250 cr., down 9%, PAT at 22% of revenue.
- Total comprehensive income at Rs. 230 cr. against Rs. 250 cr. down 8%.

Commenting on the results, Mr. Rajesh Agrawal, Jt. Managing Director said:

“Our India business has performed satisfactorily and we are seeing the recovery post GST reform. Similarly, emerging markets have posted satisfactory growth. In US, we are seeing the effect of the customer consolidation resulting in price pressure. With launch of newer products, we are hopeful to improve the performance in US in coming quarters.”

India

For Q2 FY 2018, India's branded generic sales (excluding institution) was Rs. 172 cr. posting growth of 12% and total India sales (including institution), was Rs. 178 cr., growth of 13%.

For H1 FY 2018, India branded sales (excluding institution) was Rs. 307 cr. de-growth of 1% and total India sales (including institution) was Rs. 321 cr., same level as last year.

As per IMS MAT September 2017, we have posted healthy growth of 16% in Cardiology (segment growth of 6%), 16% in Ophthalmology (segment growth of 8%), 7% in Dermatology (segment growth of 16%) and 10% in Pain Management (segment growth of 3%).

Exports

During Q2 FY 2018, export sales were Rs. 350 cr., posting growth of 2%. Africa contributed Rs. 218 cr., growth of 25%, Asia contributed Rs. 104 cr., growth of 6% and US contributed Rs. 26 cr. de-growth of 63%.

For H1 FY 2018, exports sales grew 5% with sale of Rs. 671 cr. Africa contributed Rs. 387 cr. (growth of 5%), Asia contributed Rs. 200 cr. (growth of 5%) and US contributed Rs. 81 cr. same level as last year.

In US, we received 3 ANDA final approvals, commercialized 2 products and filed 4 ANDAs with US FDA during Q2 FY 2018. With this, company has 15 products commercialized out of 21 final ANDA approvals, has 2 tentative approvals and 16 ANDAs awaiting approval with US FDA at the end of Q2 FY 2018. Company plans to file 12-15 ANDAs during this financial year.

R&D

During Q2 FY 2018, R&D expenses were Rs. 48 cr., 9% of operating revenue (Q2 FY 2017 Rs. 37 cr.). For H1 FY 2018, R&D expenses were Rs. 95 cr., 9% of operating revenue (H1 FY 2017 Rs. 69 cr.).

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 850+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 5 years, company has posted healthy performance with its consolidated total income growing at 21% CAGR and net profit at 46% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter and six months ended 30 September 2017

₹ in Crore

Particulars	3 months ended			6 months ended		Year Ended 31/03/2017
	30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016	
Income						
Revenue from operations	540.38	473.12	515.82	1,013.50	991.72	2,001.64
Other income	9.18	1.54	6.66	10.72	9.07	23.86
Total Income	549.56	474.66	522.48	1,024.22	1,000.79	2,025.50
Expenses						
Cost of materials consumed	82.33	94.45	104.31	176.78	199.94	377.85
Purchases of stock-in-trade	19.01	15.93	11.63	34.94	20.81	47.36
Changes in inventories of finished goods, work-in-progress and stock-in-trade	7.69	(16.75)	0.61	(9.06)	(4.84)	(10.62)
Employee benefits expense	89.42	86.68	72.16	176.10	142.48	295.42
Finance costs	0.09	0.07	0.29	0.16	0.69	1.36
Depreciation and amortisation expense	14.55	13.42	13.99	27.97	26.99	61.21
Other expenses	158.20	162.13	154.37	320.33	291.58	604.75
Total Expenses	371.29	355.93	357.36	727.22	677.65	1,377.33
Profit before tax	178.27	118.73	165.12	297.00	323.14	648.17
Tax Expense						
Current Tax	36.41	23.83	46.85	60.24	85.88	157.49
Deferred Tax	9.97	0.11	(12.39)	10.08	(12.95)	(16.15)
Profit for the period	131.89	94.79	130.66	226.68	250.21	506.83
Other Comprehensive Income (OCI)						
Items that will not be reclassified to profit or loss (net)	(0.03)	(0.03)	(0.05)	(0.06)	(0.11)	(0.11)
Items that will be reclassified to profit or loss	1.71	1.84	(5.71)	3.55	(0.52)	(2.42)
Other Comprehensive Income for the year, net of tax	1.68	1.81	(5.76)	3.49	(0.63)	(2.53)
Total Comprehensive Income for the period	133.57	96.60	124.90	230.17	249.58	504.30
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69	17.69	17.69
Other Equity	NA	NA	NA	1,780.71	1,423.86	1,549.99
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	14.99	10.77	14.85	25.76	28.43	57.59
(b) Diluted - in ₹	14.98	10.77	14.85	25.75	28.43	57.58

- Notes :**
- Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 31 October 2017.
 - Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended 30 September 2017.
 - The consolidated audited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
 - Deferred tax includes MAT credit of ₹ 1.26 Crores.
 - During the quarter, 8,500 (half year 9,500) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ 17,000 (half year ₹ 19,000) and securities premium account by ₹ 1.24 crores (half year ₹ 1.36 crores).
 - The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
 - There are no exceptional items.
 - The amalgamation of Gabs Investments Private Limited ('Gabs') with the Company as approved by Board of Directors on 18 March 2017, has also been approved by the Shareholders of both the Companies in their meeting held on 10 October 2017. Gabs holds 83,92,262 equity shares in the Company, representing about 9.54% of the total paid up capital, against which Company will issue same number of shares to the shareholders of Gabs. Amalgamation is subject to approval of regulatory authorities as prescribed in law. Hence, no effect of the same is given in the financial statements.
 - The Standalone Financial Results are available on the company's website www.ajantapharma.com.



10. Statement of Assets and Liabilities

₹ in Crore

Particulars	30/09/2017 Unaudited	31/03/2017 Audited
ASSETS		
Non-Current Assets		
Property, Plant and Equipment		
Capital Work-in-Progress	902.44	583.16
Other Intangible Assets	94.44	338.03
Intangible assets under development	7.79	6.01
Financial Assets	-	1.23
Investments		
Others	0.00	0.00
Deferred tax assets (Net)	12.27	9.29
Other non-current assets	29.13	24.45
Total Non-Current Assets	1,079.91	976.10
Current Assets		
Inventories	264.88	211.02
Financial Assets		
Investments	245.19	181.56
Trade Receivables	400.83	321.84
Cash and cash equivalents	65.07	51.92
Other bank balances	0.42	4.12
Other financial asset	-	1.24
Current tax assets (net)	6.57	11.23
Other current assets	71.66	63.68
Total Current Assets	1,054.62	846.61
Total Assets	2,134.53	1,822.71
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	17.69	17.69
Other Equity	1,780.71	1,549.99
Total Equity	1,798.40	1,567.68
Non-Current Liabilities		
Financial Liabilities		
Borrowings	1.03	1.04
Other financial liabilities	-	0.09
Provisions	4.95	3.15
Deferred tax liabilities (Net)	42.01	27.34
Total Non-Current Liabilities	47.99	31.62
Current Liabilities		
Financial Liabilities		
Trade Payables	187.58	139.57
Other financial liabilities	61.60	31.05
Other current liabilities	24.08	39.99
Provisions	14.88	12.80
Total Current Liabilities	288.14	223.41
Total Liabilities	336.13	255.03
Total Equity and Liabilities	2,134.53	1,822.71

11. Previous period's figures have been regrouped wherever necessary.

Mumbai, 31 October 2017

Page 2 of 2



By order of the Board
For Ajanta Pharma Ltd.


Rajesh M. Agrawal
Jt. Managing Director

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 September 2017

₹ in Crore

Particulars	3 months ended			6 months ended		Year Ended
	30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016	31/03/2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	469.14	397.93	477.74	867.07	895.61	1,822.71
Other income	7.93	2.98	6.68	10.91	9.05	66.95
Total Income	477.07	400.91	484.42	877.98	904.66	1,889.66
Expenses						
Cost of materials consumed	81.14	93.80	102.80	174.94	197.24	373.31
Purchases of stock-in-trade	14.64	18.59	14.77	33.23	25.58	59.23
Changes in inventories of finished goods, work-in-progress and stock-in-trade	10.84	(32.39)	3.53	(21.55)	0.49	7.29
Employee benefits expense	82.15	79.78	66.63	161.93	131.41	269.78
Finance costs	0.05	0.04	0.26	0.09	0.62	1.24
Depreciation and amortisation expense	13.95	12.93	13.45	26.88	25.88	59.48
Other expenses	122.93	126.36	121.39	249.29	223.69	478.68
Total Expenses	325.70	299.11	322.83	624.81	604.91	1,249.01
Profit before tax	151.37	101.80	161.59	253.17	299.75	640.65
Tax Expense						
Current Tax	32.35	21.73	42.70	54.08	78.53	136.98
Deferred Tax	11.32	3.34	(2.06)	14.66	0.36	3.86
Profit for the period	107.70	76.73	120.95	184.43	220.86	499.81
Other Comprehensive Income (OCI)						
Items that will not be reclassified to profit or loss	(0.05)	(0.04)	(0.08)	(0.09)	(0.17)	(0.17)
Items that will be reclassified to profit or loss	0.02	0.01	0.03	0.03	0.06	0.06
Other Comprehensive Income for the year, net of tax	(0.03)	(0.03)	(0.05)	(0.06)	(0.11)	(0.11)
Total Comprehensive Income for the period	107.67	76.70	120.90	184.37	220.75	499.70
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69	17.69	17.69
Other Equity	NA	NA	NA	1,671.15	1,335.05	1,486.25
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	12.24	8.72	13.75	20.96	25.10	56.79
(b) Diluted - in ₹	12.23	8.72	13.74	20.95	25.09	56.78

- Notes :**
- Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 31 October 2017.
 - Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended 30 September 2017.
 - Deferred tax includes MAT credit of ₹ 1.26 Crores.
 - During the quarter, 8,500 (half year 9,500) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ 17,000 (half year ₹ 19,000) and securities premium account by ₹ 1.24 crores (half year ₹ 1.36 crores).
 - The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
 - There are no exceptional items.
 - The amalgamation of Gabs Investments Private Limited ('Gabs') with the Company as approved by Board of Directors on 18 March 2017, has also been approved by the Shareholders of both the Companies in their meeting held on 10 October 2017. Gabs holds 83,92,262 equity shares in the Company, representing about 9.54% of the total paid up capital, against which Company will issue same number of shares to the shareholders of Gabs. Amalgamation is subject to approval of regulatory authorities as prescribed in law. Hence, no effect of the same is given in the financial statements.



8. Statement of Assets and Liabilities

₹ in Crore


Particulars	30/09/2017 Unaudited	31/03/2017 Audited
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	885.66	566.97
Capital Work-in-Progress	94.44	338.03
Other Intangible Assets	7.72	5.96
Intangible assets under development	-	1.23
Financial Assets		
Investments	17.26	17.26
Others	12.05	9.09
Other non-current assets	33.84	13.93
Total Non-Current Assets	1,050.97	952.47
Current Assets		
Inventories	246.05	179.28
Financial Assets		
Investments	245.19	181.56
Trade Receivables	406.76	336.00
Cash and cash equivalents	18.78	4.81
Other bank balances	0.42	4.12
Other financial asset	-	1.24
Current tax assets (net)	6.57	11.23
Other current assets	64.54	54.15
Total Current Assets	988.31	772.39
Total Assets	2,039.28	1,724.86
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	17.69	17.69
Other Equity	1,671.15	1,486.25
Total Equity	1,688.84	1,503.94
Non-Current Liabilities		
Financial Liabilities		
Other financial liabilities	-	0.09
Provisions	4.95	3.15
Deferred tax liabilities (Net)	42.01	27.38
Total Non-Current Liabilities	46.96	30.62
Current Liabilities		
Financial Liabilities		
Trade Payables	187.58	138.78
Other financial liabilities	60.64	30.81
Other current liabilities	40.38	7.91
Provisions	14.88	12.80
Total Current Liabilities	303.48	190.30
Total Liabilities	350.44	220.92
Total Equity and Liabilities	2,039.28	1,724.86

9. Previous period's figures have been regrouped wherever necessary.

Mumbai, 31 October 2017

Page 2 of 2

By order of the Board
For Ajanta Pharma Ltd.

Rajesh M. Agrawal
Jt. Managing Director